Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays

Publication date: 13 February 2017
Source:Cancer Cell, Volume 31, Issue 2
Author(s): Jun Li, Wei Zhao, Rehan Akbani, Wenbin Liu, Zhenlin Ju, Shiyun Ling, Christopher P. Vellano, Paul Roebuck, Qinghua Yu, A. Karina Eterovic, Lauren A. Byers, Michael A. Davies, Wanleng Deng, Y.N. Vashisht Gopal, Guo Chen, Erika M. von Euw, Dennis Slamon, Dylan Conklin, John V. Heymach, Adi F. Gazdar, John D. Minna, Jeffrey N. Myers, Yiling Lu, Gordon B. Mills, Han Liang
Cancer cell lines are major model systems for mechanistic investigation and drug development. However, protein expression data linked to high-quality DNA, RNA, and drug-screening data have not been available across a large number of cancer cell lines. Using reverse-phase protein arrays, we measured expression levels of ∼230 key cancer-related proteins in >650 independent cell lines, many of which have publically available genomic, transcriptomic, and drug-screening data. Our dataset recapitulates the effects of mutated pathways on protein expression observed in patient samples, and demonstrates that proteins and particularly phosphoproteins provide information for predicting drug sensitivity that is not available from the corresponding mRNAs. We also developed a user-friendly bioinformatic resource, MCLP, to help serve the biomedical research community.

Graphical abstract

Teaser

Li et al. analyze the levels of cancer-related total and phosphorylated proteins using RPPA in a large set of human cancer cell lines, many also with DNA, RNA, and drug-screening data available. These proteins can recapitulate mutational patterns seen in patients and show ability to predict drug sensitivity.


http://ift.tt/2ktI4Mt